Quantcast
Last updated on April 16, 2014 at 13:39 EDT

Latest APG101 Stories

2014-04-09 12:31:10

VAL-083 therapy is well tolerated to date; dose limiting toxicity has not been reached after fifth cohort (20mg/m2) VANCOUVER, British Columbia and MENLO PARK, Calif., April 9, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced an update on its ongoing Phase I/II clinical trial with VAL-083 in the treatment of refractory glioblastoma multiforme (GBM). The company's new data are being presented in a poster entitled, "A Phase I/II Study of VAL-083 in...

2014-01-13 08:30:13

Topline Data Will Be Presented at Biotech Showcase HEIDELBERG, Germany, Jan. 13, 2014 /PRNewswire/ -- Apogenix, a clinical stage biopharmaceutical company, announced today the successful completion of its phase II proof-of-concept trial with APG101 in patients with recurrent glioblastoma. All endpoints of the randomized controlled trial that compared the efficacy and safety of a combination therapy of APG101 and radiotherapy versus radiotherapy alone were achieved or...

2014-01-07 08:32:13

HEIDELBERG, Germany, Jan. 7, 2014 /PRNewswire/ -- Apogenix, a clinical stage biopharmaceutical company, announced today that Thomas Hoeger, Ph.D., Chief Executive Officer, will present the results of the completed phase II efficacy trial in patients with recurrent glioblastoma at the Biotech Showcase(TM) in San Francisco. The presentation will take place on Tuesday, Jan. 14, at 4 p.m. PST at the Parc 55 Wyndham San Francisco - Union Square. "The results of this controlled phase II...

2013-12-30 08:26:17

First European Patient In Trial Operated On In June, Profiled In BBC Report BETHESDA, Md., Dec. 30, 2013 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that the British Broadcasting Company (BBC) TV network has broadcast a report profiling the first European patient in the Company's Phase III clinical trial of DCVax-L for Glioblastoma...

2013-12-20 08:25:46

SYDNEY, Dec. 20, 2013 /PRNewswire/ -- Novogen Limited, an oncology drug development company, announced today the signing of a Sponsored Research Agreement with Cornell University. The Weill Cornell Medical College (WCMC) in New York will become the cornerstone of a collaboration across Europe, US, Asia and Australia involving universities and biotechnology companies seeking a treatment capable of delivering long-term remission for the main form of primary brain cancer, glioblastoma...

2013-12-05 08:31:00

Data Published in Molecular Cancer Therapeutics Underlines Potential of Drug Candidate in Cancer Treatment HEIDELBERG, Germany, Dec. 5, 2013 /PRNewswire/ -- Apogenix, a clinical stage biopharmaceutical company, announced today that the data published in the December issue of Molecular Cancer Therapeutics demonstrate effective antitumor activity of the company's drug candidate APG350, an activator for TRAIL receptors. The publication shows that APG350's novel molecular structure...

2013-11-26 16:24:38

HOUSTON, Nov. 26, 2013 /PRNewswire/ -- The Burzynski Clinic (BC) announced today that it has presented the results of a phase II study of antineoplastons A10 and AS2-1 (ANP) in adult patients with recurrent glioblastoma multiforme (GBM) at the 4(th) Quadrennial Meeting of the World Federation of Neuro-Oncology in San Francisco. GBM accounts for 60% of the primary brain tumors in adults and represents the most frequently occurring and the most malignant form of such tumors. Treatment...

2013-11-22 08:23:18

VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 22, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") today announced the presentation of interim data from a Phase 1/2 clinical trial for VAL-083 in recurrent glioblastoma (GBM) at the 4(th) Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18(th) Annual Society for Neuro-Oncology (SNO) meeting in San Francisco. Enrollment in the...

2013-09-30 14:19:00

Results from a clinical trial of a new treatment for glioblastoma suggest that researchers may have found a new approach to treating this most aggressive of brain tumors, as well as a potential new biological marker than can predict the tumor's response to treatment. Presenting the research to the 2013 European Cancer Congress (ECC2013) today (Monday), Professor Wolfgang Wick will say that combining radiotherapy with an anti-cancer drug called APG101 – a fusion protein similar to an...

2013-07-02 08:27:37

HEIDELBERG, Germany, July 2, 2013 /PRNewswire/ -- Apogenix GmbH, a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases, announced today that it was able to expand the patent protection for its lead product candidate Apocept(TM) (APG101). The company was recently granted two patents that cover the medical use of Apocept (APG101) in Europe and Canada. The European patent protects the medical use of CD95...